Table 3.
Percent of Samples Positive Over Time for Saliva Antibodies to Spike-f or NC-C Compared to a Clinically Validated SARSCOV-2 Antibody Test of Serum
| Convalescence, mo | Serum Ab | Saliva IgG | Saliva IgA | ||
|---|---|---|---|---|---|
| SARS CoV-2 | Spike-f | NC-C | Spike-f | NC-C | |
| <3 | 88.9 | 100.0 | 88.9 | 55.6 | 22.2 |
| 3–8 | 90.9 | 84.8 | 69.7* | 12.5**** | 3.1** |
| 9 | 96.9 | 87.5 | 56.2**** | 9.7**** | 6.5**** |
Data are percent of samples positive.
* P < .05, ** P < .01, ****P < .0001 significance compared to clinical SARS-Cov-2 serum antibody diagnosis determined by N − 1 χ 2 test [23, 24].
Abbreviations: Ab, antibody; IgA, immunoglobulin A; IgG, immunoglobulin G; NC-C, nucleocapsid c-terminal chain; SARS CoV-2, severe acute respiratory syndrome coronavirus 2; Spike-f, spike glycoprotein.